South Korea's Green Cross Begins "Test Production" of Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean pharmaceutical company Green Cross recently started "test production" of its own A/H1N1 flu vaccine, after receiving a virus strain from the UK's National Institution for Biological Standards and Control and from the Centers for Disease Control and Prevention of the U.S
You may also be interested in...
South Korea Gearing Up To Fight Tuberculosis
To eliminate perceptions that South Korea stands out among OECD countries as a safe haven for TB, the government is rolling out specific tools to combat the deadly lung disease.
Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand
SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand
Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand
SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand